Target- |
MechanismCell replacements |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date06 Jul 2016 |
Target- |
MechanismCell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multimodality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury
This is the proof of concept study with multi-modality approach (using intra-thecal bioactive peptides, stem cells, laser and transcranial IV laser and Median Nerve stimulation as adjuvants) in cases of brain death due to traumatic brain injury having diffuse axonal injury to document possibility of reversal of brain death (BD).
100 Clinical Results associated with Revita Life Sciences
0 Patents (Medical) associated with Revita Life Sciences
100 Deals associated with Revita Life Sciences
100 Translational Medicine associated with Revita Life Sciences